NFKB1 and acute lymphoblastic leukemia: These observations prompted us to evaluate whether T-ALL cells were more susceptible to a dual inhibition of the SERCA pump and NF-κB. Targeting the NF-κB pathway in Notch1 mutant T-ALL cells has already been proposed,4, 15 but the combination of an NF-κB and a SERCA pump inhibitor has not been reported so far.